Sensitization of Pancreatic Cancers to Gemcitabine Chemoradiation by WEE1 Kinase Inhibition Depends on Homologous Recombination Repair

被引:74
作者
Kausar, Tasneem [1 ]
Schreiber, Jason S. [1 ]
Karnak, David [1 ]
Parsels, Leslie A. [2 ]
Parsels, Joshua D. [2 ]
Davis, Mary A. [1 ]
Zhao, Lili [3 ]
Maybaum, Jonathan [2 ]
Lawrence, Theodore S.
Morgan, Meredith A. [1 ]
机构
[1] Univ Michigan, Dept Radiat Oncol, Sch Med, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Dept Pharmacol, Sch Med, Ann Arbor, MI 48109 USA
[3] Univ Michigan, Ctr Comprehens Canc, Biostat Unit, Ann Arbor, MI 48109 USA
来源
NEOPLASIA | 2015年 / 17卷 / 10期
基金
美国国家卫生研究院;
关键词
DNA-DAMAGE RESPONSE; TUMOR-CELLS; G(2) CHECKPOINT; IN-VITRO; RADIATION; MK-1775; PHOSPHORYLATION; EFFICACY; RADIOSENSITIZATION; REPLICATION;
D O I
10.1016/j.neo.2015.09.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To improve the efficacy of chemoradiation therapy for locally advanced pancreatic cancer and begin to establish patient selection criteria, we investigated the combination of the WEE1 inhibitor AZD1775 with gemcitabine-radiation in homologous recombination (HR) repair proficient and deficient pancreatic cancers. Sensitization to gemcitabine-radiation by AZD1775 was assessed in pancreatic cancer cells by clonogenic survival and in patient-derived xenografts by tumor growth. The contributions of HR repair inhibition and G2 checkpoint abrogation to sensitization were assessed by gamma H2AX, BRCA2 manipulation, and RAD51 focus formation and pHistone H3 flow cytometry, respectively. We found that AZD1775 sensitized to gemcitabine-radiation in BRCA2 wild-type but not BRCA2 mutant pancreatic cancer cells. In all cells, AZD1775 caused inhibition of CDK1 phosphorylation and G2 checkpoint abrogation. However, sensitization by AZD1775 was associated with persistent gamma H2AX and inhibition of RAD51 focus formation. In HR-proficient (BRCA2 wild-type) or -deficient (BRAC2 null) isogenic cells, AZD1775 sensitized to gemcitabine-radiation in BRCA2 wild-type, but not in BRCA2 null cells, despite significant G2 checkpoint abrogation. In patient-derived pancreatic tumor xenografts, AZD1775 significantly inhibited tumor growth and impaired RAD51 focus formation in response to gemcitabine-radiation. In conclusion, WEE1 inhibition by AZD1775 is an effective strategy for sensitizing pancreatic cancers to gemcitabine chemoradiation. Although this sensitization is accompanied by inhibition of CDK1 phosphorylation and G2 checkpoint abrogation, this mechanism is not sufficient for sensitization. Our findings demonstrate that sensitization to chemoradiation by WEE1 inhibition results from inhibition of HR repair and suggest that patient tumors without underlying HR defects would benefit most from this therapy.
引用
收藏
页码:757 / 766
页数:10
相关论文
共 51 条
[1]   Functional Genetic Screen Identifies Increased Sensitivity to WEE1 Inhibition in Cells with Defects in Fanconi Anemia and HR Pathways [J].
Aarts, Marieke ;
Bajrami, Ilirjana ;
Herrera-Abreu, Maria T. ;
Elliott, Richard ;
Brough, Rachel ;
Ashworth, Alan ;
Lord, Christopher J. ;
Turner, Nicholas C. .
MOLECULAR CANCER THERAPEUTICS, 2015, 14 (04) :865-876
[2]  
Ashwell S, 2012, DNA REPAIR IN CANCER THERAPY: MOLECULAR TARGETS AND CLINICAL APPLICATIONS, P211, DOI 10.1016/B978-0-12-384999-1.10010-1
[3]   Cyclin-Dependent Kinase Suppression by WEE1 Kinase Protects the Genome through Control of Replication Initiation and Nucleotide Consumption [J].
Beck, Halfdan ;
Nahse-Kumpf, Viola ;
Larsen, Marie Sofie Yoo ;
O'Hanlon, Karen A. ;
Patzke, Sebastian ;
Holmberg, Christian ;
Mejlvang, Jakob ;
Groth, Anja ;
Nielsen, Olaf ;
Syljuasen, Randi G. ;
Sorensen, Claus Storgaard .
MOLECULAR AND CELLULAR BIOLOGY, 2012, 32 (20) :4226-4236
[4]   A Phase I/II Trial of Intensity Modulated Radiation (IMRT) Dose Escalation With Concurrent Fixed-dose Rate Gemcitabine (FDR-G) in Patients With Unresectable Pancreatic Cancer [J].
Ben-Josef, Edgar ;
Schipper, Mathew ;
Francis, Isaac R. ;
Hadley, Scott ;
Ten-Haken, Randall ;
Lawrence, Theodore ;
Normolle, Daniel ;
Simeone, Diane M. ;
Sonnenday, Christopher ;
Abrams, Ross ;
Leslie, William ;
Khan, Gazala ;
Zalupski, Mark M. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (05) :1166-1171
[5]   MK-1775, a Novel Wee1 Kinase Inhibitor, Radiosensitizes p53-Defective Human Tumor Cells [J].
Bridges, Kathleen A. ;
Hirai, Hiroshi ;
Buser, Carolyn A. ;
Brooks, Colin ;
Liu, Huifeng ;
Buchholz, Thomas A. ;
Molkentine, Jessica M. ;
Mason, Kathryn A. ;
Meyn, Raymond E. .
CLINICAL CANCER RESEARCH, 2011, 17 (17) :5638-5648
[6]   WEE1 Kinase Inhibition Enhances the Radiation Response of Diffuse Intrinsic Pontine Gliomas [J].
Caretti, Viola ;
Hiddingh, Lotte ;
Lagerweij, Tonny ;
Schellen, Pepijn ;
Koken, Phil W. ;
Hulleman, Esther ;
van Vuurden, Dannis G. ;
Vandertop, W. Peter ;
Kaspers, Gertjan J. L. ;
Noske, David P. ;
Wurdinger, Thomas .
MOLECULAR CANCER THERAPEUTICS, 2013, 12 (02) :141-150
[7]   FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer [J].
Conroy, Thierry ;
Desseigne, Francoise ;
Ychou, Marc ;
Bouche, Olivier ;
Guimbaud, Rosine ;
Becouarn, Yves ;
Adenis, Antoine ;
Raoul, Jean-Luc ;
Gourgou-Bourgade, Sophie ;
de la Fouchardiere, Christelle ;
Bennouna, Jaafar ;
Bachet, Jean-Baptiste ;
Khemissa-Akouz, Faiza ;
Pere-Verge, Denis ;
Delbaldo, Catherine ;
Assenat, Eric ;
Chauffert, Bruno ;
Michel, Pierre ;
Montoto-Grillot, Christine ;
Ducreux, Michel .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (19) :1817-1825
[8]   Phase II Trial of Cetuximab, Gemcitabine, and Oxaliplatin Followed by Chemoradiation With Cetuximab for Locally Advanced (T4) Pancreatic Adenocarcinoma: Correlation of Smad4(Dpc4) Immunostaining With Pattern of Disease Progression [J].
Crane, Christopher H. ;
Varadhachary, Gauri R. ;
Yordy, John S. ;
Staerkel, Gregg A. ;
Javle, Milind M. ;
Safran, Howard ;
Haque, Waqar ;
Hobbs, Bridgett D. ;
Krishnan, Sunil ;
Fleming, Jason B. ;
Das, Prajnan ;
Lee, Jeffrey E. ;
Abbruzzese, James L. ;
Wolff, Robert A. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (22) :3037-3043
[9]  
Do K, 2015, J CLIN ONCOL
[10]   Wee1 kinase as a target for cancer therapy [J].
Do, Khanh ;
Doroshow, James H. ;
Kummar, Shivaani .
CELL CYCLE, 2013, 12 (19) :3159-3164